… the phase I pharmacokinetic data and explores the pharmacodynamic effects of erlotinib on
HER1/EGFR activation and signaling in tissue samples from treated patients. In addition, use …

… patients had an early clinical response. The present work aims to examine erlotinib
pharmacokinetics in these patients … different covariates on the pharmacokinetic parameters. As …

… of erlotinib remains fully investigated. The primary objective of this study was to clarify the
population pharmacokinetics/pharmacodynamics of erlotinib in Japanese patients with non-…

… In a phase I study, 30 evaluating the feasibility of chronic administration of erlotinib to patients
with various advanced solid malignancies, the relationships between AUC 0–24 , C max , …

… , pharmacokinetics, and pharmacodynamics of panobinostat when combined with erlotinib
in patients … While erlotinib 150 mg daily plus panobinostat at 30 mg twice weekly had dose-…

… Although the principal objective of the study was to assess the biological and pharmacodynamic
effects of erlotinib in serially sampled skin and tumor tissues obtained before and after …

… and erlotinib, given at their full approved monotherapy doses, and to … pharmacokinetic
and pharmacodynamic markers with clinical outcome. In addition, a novel pharmacodynamic …

… pharmacokinetics of erlotinib in a large number of patients … pharmacokinetics. The second
objective was to evaluate the relationship of erlotinib exposure to diarrhea and rash in patients …

… The pharmacokinetic/pharmacodynamic properties of erlotinib in a human tumor xenograft
… of erlotinib activity and determining an appropriate dosing regimen in clinical studies. …

… The current phase I study investigated the combination of apricoxib plus erlotinib in patients
… No patient entered the study on erlotinib. Of the 8 patients with prior erlotinib or gefitinib …